Atossa Therapeutics financials
$1.99+1.53%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$8.7M | -$9.9M | -$11.4M | -$9.3M | -$9.0M | -$7.4M | -$8.9M | -$6.4M | -$7.1M | -$7.0M | -$6.0M | -$7.5M |
| Net income | -$8.5M | -$9.6M | -$10.9M | -$8.7M | -$8.4M | -$6.7M | -$6.3M | -$7.2M | -$6.0M | -$5.9M | -$7.8M | -$6.2M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.95 | $-1.11 | — | $-1.05 | $-0.98 | $-0.78 | $-0.75 | $-0.90 | $-0.75 | $-0.75 | $-0.93 | $-0.75 |
| EBITDA | -$8.7M | -$9.9M | -$11.4M | -$9.2M | -$9.0M | -$7.4M | -$7.1M | -$6.4M | -$7.1M | -$7.0M | -$9.0M | -$7.5M |
| Operating cash flow | -$9.6M | -$9.6M | -$10.5M | -$6.0M | -$7.3M | -$6.0M | -$7.1M | -$4.8M | -$4.5M | -$4.7M | -$5.6M | -$3.9M |
| Free cash flow | -$9.6M | -$9.6M | -$10.5M | -$6.0M | -$7.3M | -$6.0M | -$7.1M | -$4.8M | -$4.5M | -$4.7M | -$5.6M | -$3.9M |
| Diluted shares | 8.9M | 8.6M | — | 8.6M | 8.6M | 8.6M | 8.4M | 8.4M | 8.4M | 8.4M | 8.4M | 8.4M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $26.1M | $31.7M | $41.3M | $51.8M | $57.9M | $65.1M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $32.3M | $37.9M | $47.6M | $58.0M | $64.5M | $70.7M |
| Total liabilities | $5.5M | $7.5M | $8.3M | $8.2M | $6.8M | $5.4M |
| Shareholders' equity | $26.8M | $30.5M | $39.4M | $49.8M | $57.7M | $65.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology